ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.1644G>A (p.Gln548=) (rs55986646)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000112947 SCV000578019 benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; http://priors.hci.utah.edu/PRIORS/) and frequency 0.0032 (East Asian), derived from ExAC (2014-12-17).
Invitae RCV001080641 SCV000071864 benign Hereditary breast and ovarian cancer syndrome 2020-11-23 criteria provided, single submitter clinical testing
Ambry Genetics RCV000162904 SCV000213391 likely benign Hereditary cancer-predisposing syndrome 2014-12-10 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Color Health, Inc RCV000162904 SCV000683434 benign Hereditary cancer-predisposing syndrome 2015-11-30 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000501303 SCV000694551 benign not specified 2019-05-02 criteria provided, single submitter clinical testing Variant summary: BRCA2 c.1644G>A alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00024 in 274202 control chromosomes, predominantly at a frequency of 0.0034 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 5 fold of the estimated maximal expected allele frequency for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer phenotype (0.00075), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.1644G>A has been reported in the literature in individuals with personal and/or family history of Hereditary Breast and Ovarian Cancer (Hwang_2017, Trujillano_2015, Thirthagiri_2008, Suter_2004). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with a pathogenic variant have been reported (BRCA2 c.1212delT, p.Asn404Lysfs*26; UMD), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four ClinVar submitters including an expert panel (ENIGMA) (evaluation after 2014) cite the variant as benign. Based on the evidence outlined above, the variant was classified as benign.
Breast Cancer Information Core (BIC) (BRCA2) RCV000112947 SCV000145904 benign Breast-ovarian cancer, familial 2 2010-09-18 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000112947 SCV000591758 benign Breast-ovarian cancer, familial 2 no assertion criteria provided clinical testing The BRCA2 p.Gln548Gln variant was identified in the literature in one Chinese family with hereditary breast and ovarian cancer (Thirthagiri 2008); however, control chromosomes from healthy individuals were not evaluated in this study. The variant was also identified in dbSNP (ID: rs rs55986646) “With likely benign allele”, in the 1000 Genomes Project, in 1 of 5000 chromosomes (frequency 0.0002). It was also identified in the Exome Aggregation Consortium (ExAC) database (January 13, 2015) in 28 of 121014 chromosomes (frequency: 0.0002) (or 28 individuals from a population of 8644 East Asian individuals (frequency: 0.003)), and not from European (Non-Finnish)/African/Latino/South Asian/European (Finnish) or other individuals; the Clinvitae database classified the variant as benign/likely benign; ClinVar (4X, classified as a benign by BIC and GeneDX; likely benign by Ambry Genetics), and UMD (2X as a 3-unclassified variant variant, co-occurring with a pathogenic BRCA2 variant (c.1212delT (p.Asn404LysfsX26), increasing the likelihood that the p.Gln548Gln variant does not have clinical significance). The variant was also identified by our laboratory in 3 individuals with breast, and ovarian cancer including one with a co-occurring pathogenic variant (BRCA2 c.246delA), increasing the likelihood the p.Gln548Gln variant does not have clinical significance. The p.Gln548Gln variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, four out of five in-silico splicing tools predict abolishment of a 3’ splice site in a region not expected to be involved in splicing, but this information is not very predictive of pathogenicity. In summary, based on the above information, this variant meets our laboratories criteria to be classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.